Holen Sie sich die Stockscreener-App
3.39
10.79%
-0.41
Schlusskurs vom Vortag:
$3.80
Offen:
$3.81
24-Stunden-Volumen:
492.19K
Relative Volume:
0.51
Marktkapitalisierung:
$61.59M
Einnahmen:
$114.73M
Nettoeinkommen (Verlust:
$-140.94M
KGV:
-1.2283
EPS:
-2.76
Netto-Cashflow:
$-126.18M
1W Leistung:
-24.67%
1M Leistung:
-33.79%
6M Leistung:
-74.34%
1J Leistung:
-72.44%
1-Tages-Spanne:
$3.36
$3.96
1-Wochen-Bereich:
$3.36
$4.9212
52-Wochen-Spanne:
$3.10
$21.98
Outset Medical Inc Stock (OM) Company Profile
Firmenname
Outset Medical Inc
Sektor
Branche
Telefon
669-231-8200
Adresse
3052 ORCHARD DRIVE, SAN JOSE
Compare OM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OM
Outset Medical Inc
|
3.39 | 69.04M | 114.73M | -140.94M | -126.18M | -2.76 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Outset Medical Inc Stock (OM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-06-21 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-04-08 | Eingeleitet | BTIG Research | Buy |
| 2024-04-05 | Hochstufung | CL King | Neutral → Buy |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-13 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-17 | Eingeleitet | CL King | Neutral |
| 2022-11-11 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-07-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-08-18 | Eingeleitet | Cowen | Outperform |
| 2021-04-19 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-16 | Eingeleitet | Oppenheimer | Perform |
| 2020-10-12 | Eingeleitet | Barclays | Overweight |
| 2020-10-12 | Eingeleitet | BofA Securities | Buy |
| 2020-10-12 | Eingeleitet | Goldman | Buy |
| 2020-10-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-12 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Outset Medical Inc Aktie (OM) Neueste Nachrichten
Outset Medical, Inc. (NASDAQ:OM) Q4 2025 Earnings Call Transcript - Insider Monkey
US$10.50: That's What Analysts Think Outset Medical, Inc. (NASDAQ:OM) Is Worth After Its Latest Results - Yahoo Finance
Outset Medical Earnings Call Highlights Margin Turnaround - TipRanks
Outset Medical (NASDAQ:OM) Given New $15.00 Price Target at BTIG Research - MarketBeat
Outset Medical, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BTIG Lowers Price Target for Outset Medical (OM) to $15, Maintai - GuruFocus
Outset Medical stock dips on Q4 EPS miss - MassDevice
What’s the fair value of Outset Medical Inc. stockJuly 2025 Spike Watch & Verified Swing Trading Watchlists - mfd.ru
Outset Medical Inc (OM) Q4 2025 Earnings Call Highlights: Strate - GuruFocus
Outset Medical: Stabilizing Execution, Improving Margins, and Balanced 2026 Outlook Support Buy Rating Despite Lower Target - TipRanks
Earnings call transcript: Outset Medical Q4 2025 reports revenue growth By Investing.com - Investing.com India
Outset Medical (OM) Sets 2026 Revenue and Margin Targets - GuruFocus
Outset Medical Q4 Earnings Call Highlights - Yahoo Finance
Outset Medical earnings missed by $0.60, revenue fell short of estimates - Investing.com Canada
OM: Revenue up 5% to $119.5M, margin expands, and next-gen Tablo FDA-cleared for 2026 growth - TradingView
Earnings call transcript: Outset Medical Q4 2025 reports revenue growth - Investing.com
Outset Medical Inc. (OM) Misses Q4 EPS by 60c - StreetInsider
Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Outset Medical Q4 Earnings Report: What Investors Need to Know - Benzinga
Dialysis device maker Outset cuts 2025 loss to $81.7M, gets FDA clearance - Stock Titan
Fund Flows: Can Outset Medical Inc sustain earnings growth2025 Valuation Update & Verified Technical Trade Signals - baoquankhu1.vn
Outset Medical Q4 2025 Earnings Call Transcript - MarketBeat
Outset Medical Q4 2025 earnings preview - MSN
Outset Medical Inc (OM) Q4 2025: Everything You Need To Know Ahe - GuruFocus
Stifel Lowers Price Target on Outset Medical, Inc. (OM) to $8, Maintains Buy Rating - Finviz
Stifel lowers price target on Outset Medical, Inc. (OM) to $8, maintains buy rating - MSN
11 High Growth Micro-cap Stocks to Buy - Insider Monkey
Outset Medical Secures Key FDA Clearance for Next-Generation Dialysis System - AD HOC NEWS
Outset Medical (NASDAQ:OM) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Outset Medical (OM) to Release Quarterly Earnings on Wednesday - MarketBeat
Outset Medical, Inc. (NASDAQ:OM) Held Back By Insufficient Growth Even After Shares Climb 35% - simplywall.st
Is Outset Medical Inc benefiting from innovation trendsJuly 2025 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Outset Medical (NASDAQ:OM) Rating Increased to Hold at Wall Street Zen - MarketBeat
What are the future prospects of Outset Medical Inc.Weekly Earnings Recap & Reliable Momentum Entry Alerts - mfd.ru
Outset Medical, Inc. (OM) Investor Outlook: Is A 133.83% Upside On The Horizon? - DirectorsTalk Interviews
OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System - sharewise.com
Quarterly Earnings: What is Outset Medical Incs 5 year growth outlookMarket Activity Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Guidance Update: Is Outset Medical Inc being accumulated by smart moneyJuly 2025 Volume & Long-Term Safe Investment Plans - baoquankhu1.vn
Outset Medical secures FDA clearance for Tablo haemodialysis system - Yahoo Finance
Outset Medical stock jumps after FDA clears next-gen Tablo platform - Investing.com Australia
Is Outset Medical Inc. stock risky to hold nowQuarterly Portfolio Report & Long-Term Growth Stock Strategies - mfd.ru
Outset Medical Gets FDA Clearance for Tablo Hemodialysis System - marketscreener.com
Outset Medical wins FDA nod for next-gen Tablo hemodialysis system - MassDevice
Outset Medical, Inc. Announces 510(K) Clearance by the U.S. Food and Drug Administration of Its Next-Generation Tablo Platform - marketscreener.com
Outset Medical Secures FDA Clearance For Next-Generation Tablo Hemodialysis System - Nasdaq
Outset Medical (OM) Gains FDA Clearance for Advanced Tablo Platf - GuruFocus
Outset Medical’s Tablo dialysis system meets FDA cybersecurity standards - Investing.com
Outset Medical Wins FDA Clearance for Next-Gen Tablo System - TipRanks
Outset Medical stock jumps after FDA clears next-gen Tablo platform By Investing.com - Investing.com Australia
Outset Medical rises after FDA clears upgraded dialysis system - TradingView
Outset Medical, Inc. Announces FDA Clearance for Next-Gen Tablo Platform - TradingView
Finanzdaten der Outset Medical Inc-Aktie (OM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Outset Medical Inc-Aktie (OM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nash Marc | EVP Operations R&D & Service |
Jan 21 '26 |
Sale |
4.98 |
980 |
4,880 |
41,805 |
| Brottem John L. | General Counsel |
Jan 20 '26 |
Sale |
5.12 |
9,314 |
47,688 |
36,957 |
| Brottem John L. | General Counsel |
Jan 21 '26 |
Sale |
5.01 |
1,180 |
5,912 |
35,777 |
| Trigg Leslie | Chair and CEO |
Jan 20 '26 |
Sale |
5.12 |
11,794 |
60,385 |
107,823 |
| Trigg Leslie | Chair and CEO |
Jan 21 '26 |
Sale |
5.05 |
2,120 |
10,706 |
105,703 |
1.33%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):